FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

Eisai announced FDA approval of a supplemental Biologics License Application for a once-weekly subcutaneous lecanemab formulation, expanding the approved dosing regimen. The approval is a meaningful regulatory milestone for the therapy’s commercial and uptake potential, supporting BioArctic/Eisai fundamentals ahead of broader adoption.

Analysis

Eisai announced FDA approval of a supplemental Biologics License Application for a once-weekly subcutaneous lecanemab formulation, expanding the approved dosing regimen. The approval is a meaningful regulatory milestone for the therapy’s commercial and uptake potential, supporting BioArctic/Eisai fundamentals ahead of broader adoption.